Physician profile
Anna Pagano
NPI 1497907679
$5,384.49
in general payments reported to CMS, 2019-2025
24 companies · $951 in 2025
The $951 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,077 · 2022: $806 · 2023: $1,464 · 2024: $1,087 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,489.53 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,117.04 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $914.87 | 2021-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $761.29 | 2021-2025 | Caplyta |
| Alkermes, INC. | $522.83 | 2021-2024 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $403.40 | 2021-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $381.06 | 2022-2025 | Auvelity |
| Corium, LLC | $167.65 | 2022-2024 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $157.18 | 2021-2024 | Trintellix |
| Bausch Health US, LLC | $137.88 | 2021-2025 | Wellbutrin, Aplenzin |
| Lundbeck LLC | $116.48 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $112.40 | 2021-2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $100.80 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $95.02 | 2021-2024 | Austedo Xr |
| Collegium Pharmaceutical, INC. | $80.26 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $72.55 | 2022-2023 | Adzenys Xr-Odt |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $53.38 | 2021 | |
| Tris Pharma INC | $50.33 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $45.58 | 2022-2024 | Qelbree |
| Owp Pharmaceuticals, INC. | $19.88 | 2022 | |
| Avanir Pharmaceuticals, INC. | $16.70 | 2022 | |
| Jazz Pharmaceuticals INC. | $15.91 | 2022 | |
| Almatica Pharma LLC | $14.94 | 2023 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $14.45 | 2024 | Fanapt |
| Heron Therapeutics, INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Pagano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.